We continually strive to reduce our impact on natural systems and the environment, with a focus on energy, greenhouse gases, water and waste. To achieve our goals, we have set specific environmental targets.

2030 Targets and 2024 Progress


The targets also reflect our diverse and evolving product portfolio, which includes the manufacturing of pharmaceutical ingredients, capsules, food supplements, gene therapy and cell media, and the licensing of technologies and systems.

With a long-term view to 2030, we want to reduce consumption considerably to align with the broadly accepted greenhouse gas reduction targets, with an ambition of reaching net-zero greenhouse gas (GHG) emissions by 2050. In February 2024, the Science-Based Targets initiative (SBTi) validated our near-term GHG emission reduction targets that were submitted in July 2023. We have committed to reducing absolute Scope 1 and 2 GHG emissions by 42% by 2030, from a 2021 base year. We also set a supplier engagement target for Scope 3 emissions, committing that 79% of our suppliers by emissions (covering purchased goods and services, capital goods and upstream transportation and distribution) will have science-based targets by 2028.

Our Focus Areas